Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Michael O'Riordan

May 30, 2024

News Daily News

Statins Effective For Primary Prevention in Old and Very Old

Michael O'Riordan

May 29, 2024

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

News Daily News

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Yael L. Maxwell

February 15, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

Presentation Controversies and Advances 2023

Anti-inflammatory Drugs to Inhibit Atherosclerosis: Old and New

Presenter: Christie M. Ballantyne

November 30, 2023

News Daily News

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Michael O'Riordan

June 14, 2023

News Daily News

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Yael L. Maxwell

April 03, 2023

News Conference News ACC 2023

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Todd Neale

March 10, 2023

Presentation ACC 2023

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Presenter: Christie Ballantyne

March 05, 2023

News Daily News

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Michael O'Riordan

March 01, 2023

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

Todd Neale

July 20, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Daily News

For Coronary Heart Disease, Upping Exercise Over Time Linked to Survival Gains

Michael O'Riordan

May 03, 2022

News Conference News AHA 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Shelley Wood

November 15, 2021

News Daily News

Statins Not Linked to Dementia or Memory Changes: ASPREE

Michael O'Riordan

June 21, 2021

News Daily News

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Michael O'Riordan

August 11, 2020

Advertisement

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Statins Effective For Primary Prevention in Old and Very Old

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Anti-inflammatory Drugs to Inhibit Atherosclerosis: Old and New

Obicetrapib Effective When Added to Statins and Ezetimibe: ROSE2

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study

Efficacy and Safety of the Oral PCSK9 Inhibitor, MK-0616, a Macrocyclic Peptide, in the Treatment of Hypercholesterolemia: A Phase 2b Randomized Placebo-Controlled Clinical Trial

Don’t Just Prescribe a Statin—Measure and Control LDL, Say NLA, ASPC

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

Good News and Bad for High-Intensity Statin Use in ASCVD

For Coronary Heart Disease, Upping Exercise Over Time Linked to Survival Gains

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Statins Not Linked to Dementia or Memory Changes: ASPREE

High-Sensitivity Troponin Hones ASCVD Risk in Secondary Prevention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content